News and Trends 10 Nov 2022 Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS …The Parkinson’s Virtual Biotech is the international drug discovery and development program founded in 2017 by Parkinson’s UK, the largest European charitable funder of Parkinson’s research. Since 2019, Virtual Biotech… November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 19 Sep 2024 Mitochondrial disease treatments: is a breakthrough on the horizon? …to the clinic in the next few weeks. It has been tested in preclinical models of Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment where it was found to improve… September 19, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug… September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Mar 2024 The 9 hottest private biotech companies in San Diego …the development of its lead cell therapy, ANPD001, which is designed to tackle Parkinson’s disease by replacing nerve cells that are killed off by the disease. While there are multiple… March 19, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Jun 2023 Six advancements in Alzheimer’s research over the past year …like Parkinson’s disease and frontotemporal dementia as well. TauRx’s drug candidate offers promise In an effort to neutralize the effect of aggregation of tau protein in the brain, life science… June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 21 Oct 2016 New Partnership comes to the Rescue in Neurological Diseases …Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and Chron’s… October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2020 French Manufacturing Plant Launches to Make Cell Therapy Cheap and Scalable …the development of in-house cell therapies for conditions such as Parkinson’s disease and heart failure. The new plant will also allow Treefrog to produce cell therapies for at least two… June 9, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 1 Dec 2025 Stem cell therapy’s avant-garde: Eight companies leading the way …makes it one of the first pluripotent stem-cell-derived therapies and the most advanced allogeneic neuronal replacement therapy to reach a pivotal study in Parkinson’s disease. Beyond its Parkinson’s program, BlueRock is expanding its… December 1, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
More News! 27 Jun 2019 German Biotech Will Target Parkinsonian Disorders with €12M Series A …is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s drug candidate prevents and stops… June 27, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Oct 2023 Five impactful biotech companies to know in New York …depression, Parkinson’s disease, and behavioral disturbances associated with Alzheimer’s disease. The company was founded on Dr. Paul Greengard’s Nobel Prize-winning research, which uncovered how therapies affect the inner workings of… October 3, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
2024 biotech funding tracker: recent highlights …AI-enabled vaccine platform | Preclinical in coronavirus March 2024: Kenai Therapeutics (USA): $82 million series A | stem cell therapy | preclinical in moderate to severe Parkinson’s disease. Tierra Biosciences… February 23, 2024 - 1 minutemin - By Aurore Michelin Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Collaboration to explore gene therapy products for neurodegenerative disorders …development of gene therapy products targeting the transcription factor EB (TFEB) for the treatment of alpha-synucleinopathies, such as Multiple System Atrophy (MSA) and idiopathic Parkinson’s disease (PD). Toxic protein aggregates… September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email